Ftse Mib
34.917,53
0,39%
DAX
20.340,57
0,65%
S&P 500
5.932,40
-0,72%
NASDAQ
19.578,74
-1,44%
Bitcoin
97.043,85
-5,13%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Poseida Therapeutics Inc (PSTX) Poseida Therapeutics Inc (PSTX) Notizie

Poseida Therapeutics Inc

PSTX
9,605
0,045 (0,47%)
Ultimo aggiornamento: 20:01:31
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/1/202514:06EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
06/1/202523:28EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
27/12/202423:28EDGAR2Form SC TO-T/A - Tender offer statement by Third Party:..
09/12/202423:26EDGAR2Form SC 14D9 - Solicitation, recommendation statements
09/12/202418:00PRNUSPoseida Therapeutics Highlights Positive Interim Phase 1..
27/11/202413:18EDGAR2Form SC14D9C - Written communication relating to third party..
26/11/202415:05APSCalifornia-Based Biotech Trading over +200% Premarket..
26/11/202412:53EDGAR2Form SC14D9C - Written communication relating to third party..
26/11/202412:49EDGAR2Form 8-K - Current report
26/11/202407:10PRNUSPoseida Therapeutics, Inc. Announces Agreement to be..
14/11/202415:15EDGAR2Form 8-K - Current report
14/11/202415:00PRNUSPoseida Therapeutics Hosts Cell Therapy R&D Day Highlighting..
11/11/202422:05PRNUSPoseida Therapeutics to Present at Two Upcoming Investor..
07/11/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202422:07EDGAR2Form 8-K - Current report
07/11/202422:05PRNUSPoseida Therapeutics Provides Updates and Financial Results..
05/11/202422:05PRNUSPoseida Therapeutics to Present Clinical and Preclinical..
24/10/202414:00PRNUSPoseida Therapeutics to Present New Preclinical Data..
22/10/202421:24EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
17/10/202414:00PRNUSPoseida Therapeutics Announces Nomination of New CAR-T..
15/10/202414:05GLOBEMaxCyte Appoints Cynthia Collins to its Board of Directors
03/10/202422:30PRNUSPoseida Therapeutics Named to Newsweek's List of the Top 200..
30/9/202414:00EDGAR2Form 8-K - Current report
27/9/202422:30PRNUSPoseida Therapeutics Reports Positive Interim Phase 1..
16/9/202414:00PRNUSPoseida Therapeutics Receives Regenerative Medicine Advanced..
05/9/202415:00PRNUSPoseida Therapeutics to Present New Clinical Data from Phase..
04/9/202422:05PRNUSPoseida Therapeutics Presents New Case Study Demonstrating..
29/8/202422:05PRNUSPoseida Therapeutics to Present at Upcoming Investor..
15/8/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
05/8/202422:33EDGAR2Form S-3 - Registration statement under Securities Act of..
05/8/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/8/202422:05EDGAR2Form 8-K - Current report
05/8/202422:05PRNUSPoseida Therapeutics Provides Updates and Financial Results..
01/7/202422:05PRNUSPoseida Therapeutics Announces Participation in Stifel's..
18/6/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202422:10EDGAR2Form 8-K - Current report
03/6/202422:05PRNUSPoseida Therapeutics Announces Virtual 2024 Annual Meeting..
14/5/202422:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202422:06EDGAR2Form 8-K - Current report
14/5/202422:05PRNUSPoseida Therapeutics Provides Updates and Financial Results..
09/5/202415:00PRNUSPoseida Highlights Strong Progress on Its Genetic Medicine..
02/5/202403:30PRNUSAstellas and Poseida Therapeutics Enter Into Research..
01/5/202421:25APSBiotech Soars on Research Collaboration And License..
01/5/202415:00PRNUSAstellas and Poseida Therapeutics Enter Into Research..
18/4/202414:00PRNUSPoseida Therapeutics Announces Strong Lineup of..
17/4/202415:00PRNUSPoseida Therapeutics Hosts Gene Therapy R&D Day Highlighting..
08/4/202418:00PRNUSPoseida Therapeutics Presents New Phase 1 Data at AACR 2024..
01/4/202422:05PRNUSPoseida Therapeutics Announces Inducement Grant Under Nasdaq..
25/3/202421:05PRNUSPoseida Therapeutics Appoints Syed Rizvi, M.D., as Chief..
Apertura: 9,578 Min: 9,575 Max: 9,67
Chiusura: 9,56

La tua Cronologia

NASDAQ
PSTX
Poseida Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network